Exploring a One-Stop Integrated Solution for AAV Vector Clinical Production
Summary: In this webinar to learn how the right process, clonal HEK293 cell line, and range of off-the-shelf plasmids, along with qualified analytical methods supports a robust supply chain for the development and manufacture of AAV vectors, and the reduction of timelines to clinical evaluation. The complete platform approach provides increased consistency and efficiency, reducing the time to manufacture clinical-quality drug product to just nine months, while delivering a process that will readily advance to late stage GMP manufacture.